Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia

Giorgia Battipaglia, Annalisa Ruggeri, Myriam Labopin, Liisa Volin, Didier Blaise, Gerard Socié, Reza Tabrizi, Jan J Cornelissen, Ardeshir Ghavamzadeh, Anne Huynh, Depei Wu, Ibrahim Yakoub-Agha, Johan Maertens, Patrice Chevallier, Mohamad Mohty, Arnon Nagler

Research output: Contribution to journalArticle

Abstract

Refined graft-versus-host disease (GVHD)/relapse-free survival (GRFS) considers main outcomes of allogeneic stem cell transplant (HSCT), estimating long-term survival without significant morbidity as a surrogate of HSCT success. We compared GRFS in 5059 adults with acute myeloid leukemia (AML), undergoing HSCT in first complete remission from 2000 to 2015 either from a matched sibling (MSD, n = 3731) or unrelated donor (MUD, n = 1328). Median age was 49 (range: 18-76) years. Median follow-up was 32 and 60 months in MSD and MUD, respectively (p < 0.01). Compared to MSD, at 4 years, MUD recipients had lower GRFS, with higher NRM, grade III-IV acute GVHD, and extensive chronic GVHD (HR: 1.42, p < 0.01). We also performed a risk factor analyses, showing unfavorable cytogenetics (HR: 1.42, p < 0.01) and peripheral blood as stem cell source (HR: 1.22, p < 0.01) associated to lower GRFS, while this was higher with in vivo T-cell depletion (TCD, HR: 0.73, p < 0.01) and shorter time from diagnosis to HSCT (HR 0.96, p < 0.01). Different factors, modifiable or not, such as donor type, stem cell source, disease biology, and in vivo TCD, impact on GRFS and this may guide in the future transplant choices to improve morbidity and long-term quality of life.

Original languageEnglish
Pages (from-to)1295-1303
Number of pages9
JournalBone Marrow Transplantation
Volume53
Issue number10
DOIs
Publication statusPublished - Oct 2018
Externally publishedYes

Fingerprint

Unrelated Donors
Graft vs Host Disease
Acute Myeloid Leukemia
Disease-Free Survival
Transplants
Recurrence
Survival
Stem Cells
Morbidity
Cytogenetics
Statistical Factor Analysis
Siblings
Quality of Life
Tissue Donors
T-Lymphocytes

Cite this

Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia. / Battipaglia, Giorgia; Ruggeri, Annalisa; Labopin, Myriam; Volin, Liisa; Blaise, Didier; Socié, Gerard; Tabrizi, Reza; Cornelissen, Jan J; Ghavamzadeh, Ardeshir; Huynh, Anne; Wu, Depei; Yakoub-Agha, Ibrahim; Maertens, Johan; Chevallier, Patrice; Mohty, Mohamad; Nagler, Arnon.

In: Bone Marrow Transplantation, Vol. 53, No. 10, 10.2018, p. 1295-1303.

Research output: Contribution to journalArticle

Battipaglia, G, Ruggeri, A, Labopin, M, Volin, L, Blaise, D, Socié, G, Tabrizi, R, Cornelissen, JJ, Ghavamzadeh, A, Huynh, A, Wu, D, Yakoub-Agha, I, Maertens, J, Chevallier, P, Mohty, M & Nagler, A 2018, 'Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia', Bone Marrow Transplantation, vol. 53, no. 10, pp. 1295-1303. https://doi.org/10.1038/s41409-018-0169-6
Battipaglia, Giorgia ; Ruggeri, Annalisa ; Labopin, Myriam ; Volin, Liisa ; Blaise, Didier ; Socié, Gerard ; Tabrizi, Reza ; Cornelissen, Jan J ; Ghavamzadeh, Ardeshir ; Huynh, Anne ; Wu, Depei ; Yakoub-Agha, Ibrahim ; Maertens, Johan ; Chevallier, Patrice ; Mohty, Mohamad ; Nagler, Arnon. / Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia. In: Bone Marrow Transplantation. 2018 ; Vol. 53, No. 10. pp. 1295-1303.
@article{73c874c62a2242bba1236a25723f60a9,
title = "Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia",
abstract = "Refined graft-versus-host disease (GVHD)/relapse-free survival (GRFS) considers main outcomes of allogeneic stem cell transplant (HSCT), estimating long-term survival without significant morbidity as a surrogate of HSCT success. We compared GRFS in 5059 adults with acute myeloid leukemia (AML), undergoing HSCT in first complete remission from 2000 to 2015 either from a matched sibling (MSD, n = 3731) or unrelated donor (MUD, n = 1328). Median age was 49 (range: 18-76) years. Median follow-up was 32 and 60 months in MSD and MUD, respectively (p < 0.01). Compared to MSD, at 4 years, MUD recipients had lower GRFS, with higher NRM, grade III-IV acute GVHD, and extensive chronic GVHD (HR: 1.42, p < 0.01). We also performed a risk factor analyses, showing unfavorable cytogenetics (HR: 1.42, p < 0.01) and peripheral blood as stem cell source (HR: 1.22, p < 0.01) associated to lower GRFS, while this was higher with in vivo T-cell depletion (TCD, HR: 0.73, p < 0.01) and shorter time from diagnosis to HSCT (HR 0.96, p < 0.01). Different factors, modifiable or not, such as donor type, stem cell source, disease biology, and in vivo TCD, impact on GRFS and this may guide in the future transplant choices to improve morbidity and long-term quality of life.",
author = "Giorgia Battipaglia and Annalisa Ruggeri and Myriam Labopin and Liisa Volin and Didier Blaise and Gerard Soci{\'e} and Reza Tabrizi and Cornelissen, {Jan J} and Ardeshir Ghavamzadeh and Anne Huynh and Depei Wu and Ibrahim Yakoub-Agha and Johan Maertens and Patrice Chevallier and Mohamad Mohty and Arnon Nagler",
year = "2018",
month = "10",
doi = "10.1038/s41409-018-0169-6",
language = "English",
volume = "53",
pages = "1295--1303",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia

AU - Battipaglia, Giorgia

AU - Ruggeri, Annalisa

AU - Labopin, Myriam

AU - Volin, Liisa

AU - Blaise, Didier

AU - Socié, Gerard

AU - Tabrizi, Reza

AU - Cornelissen, Jan J

AU - Ghavamzadeh, Ardeshir

AU - Huynh, Anne

AU - Wu, Depei

AU - Yakoub-Agha, Ibrahim

AU - Maertens, Johan

AU - Chevallier, Patrice

AU - Mohty, Mohamad

AU - Nagler, Arnon

PY - 2018/10

Y1 - 2018/10

N2 - Refined graft-versus-host disease (GVHD)/relapse-free survival (GRFS) considers main outcomes of allogeneic stem cell transplant (HSCT), estimating long-term survival without significant morbidity as a surrogate of HSCT success. We compared GRFS in 5059 adults with acute myeloid leukemia (AML), undergoing HSCT in first complete remission from 2000 to 2015 either from a matched sibling (MSD, n = 3731) or unrelated donor (MUD, n = 1328). Median age was 49 (range: 18-76) years. Median follow-up was 32 and 60 months in MSD and MUD, respectively (p < 0.01). Compared to MSD, at 4 years, MUD recipients had lower GRFS, with higher NRM, grade III-IV acute GVHD, and extensive chronic GVHD (HR: 1.42, p < 0.01). We also performed a risk factor analyses, showing unfavorable cytogenetics (HR: 1.42, p < 0.01) and peripheral blood as stem cell source (HR: 1.22, p < 0.01) associated to lower GRFS, while this was higher with in vivo T-cell depletion (TCD, HR: 0.73, p < 0.01) and shorter time from diagnosis to HSCT (HR 0.96, p < 0.01). Different factors, modifiable or not, such as donor type, stem cell source, disease biology, and in vivo TCD, impact on GRFS and this may guide in the future transplant choices to improve morbidity and long-term quality of life.

AB - Refined graft-versus-host disease (GVHD)/relapse-free survival (GRFS) considers main outcomes of allogeneic stem cell transplant (HSCT), estimating long-term survival without significant morbidity as a surrogate of HSCT success. We compared GRFS in 5059 adults with acute myeloid leukemia (AML), undergoing HSCT in first complete remission from 2000 to 2015 either from a matched sibling (MSD, n = 3731) or unrelated donor (MUD, n = 1328). Median age was 49 (range: 18-76) years. Median follow-up was 32 and 60 months in MSD and MUD, respectively (p < 0.01). Compared to MSD, at 4 years, MUD recipients had lower GRFS, with higher NRM, grade III-IV acute GVHD, and extensive chronic GVHD (HR: 1.42, p < 0.01). We also performed a risk factor analyses, showing unfavorable cytogenetics (HR: 1.42, p < 0.01) and peripheral blood as stem cell source (HR: 1.22, p < 0.01) associated to lower GRFS, while this was higher with in vivo T-cell depletion (TCD, HR: 0.73, p < 0.01) and shorter time from diagnosis to HSCT (HR 0.96, p < 0.01). Different factors, modifiable or not, such as donor type, stem cell source, disease biology, and in vivo TCD, impact on GRFS and this may guide in the future transplant choices to improve morbidity and long-term quality of life.

U2 - 10.1038/s41409-018-0169-6

DO - 10.1038/s41409-018-0169-6

M3 - Article

C2 - 29662244

VL - 53

SP - 1295

EP - 1303

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -